Articles tagged "Immunosuppression"

2018 American Transplant Congress
Comparison of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients- 3 Years Follow-Up
S. Narumi,¹ Y. Watarai,¹ N. Goto,² T. Hiramitsu,¹ M. Tsujita,² M. Okada,¹ K. Futamura,² T. Kobayashi.³
¹Transplant Surgery, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ²Transplant Nephrology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan; ³Kidney Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
2018 American Transplant Congress
Treatment of BK Viremia: Single-Center Experience
A. Karim, A. Hines, K. Wang, S. Saleh, B. Suleiman, W. Hassan, A. Maibam, M. Yaseen, A. Castellanos, V. Cornea, X. Mei, R. Gedaly, T. Waid, A. El-Husseini.
Nephrology, University of Kentucky, Lexington, KY.
INTRODUCTION:BK viremia (BKV) and BK virus nephropathy (BKVN) is recognized as an emerging problem in renal transplant recipients. Only reduction of immunosuppressants had shown efficacy…
2018 American Transplant Congress
Exploring Immunosuppressant Medication Adherence in Kidney Transplant Recipients
D. Goodall, M. Willicombe, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with poor outcomes following kidney transplantation. The aim of this study was to describe the beliefs, understanding and experience…
2018 American Transplant Congress
Association of Immunosuppressive Therapy Regimen with Sepsis Outcomes among Kidney Transplant Recipients
J. Donnelly,¹ P. MacLennan,¹ R. Mannon,¹ R. Saran,² J. Baddley,¹ H. Wang,³ G. McGwin, Jr.,¹ P. Muntner.¹
¹University of Alabama at Birmingham, Birmingham, AL; ²University of Michigan, Ann Arbor, MI; ³University of Texas Health Science Center, Houston, TX.
OBJECTIVE: Immunosuppressive therapy (IST) could impact sepsis outcomes by altering the host immune response. We examined the associations of IST regimens with sepsis outcomes among…
2018 American Transplant Congress
Polyclonal Cellular Immune Function is Dose-Dependently Inhibited by Immunosuppressive Drugs but Has Limited Value in Predicting Infection or Rejection Episodes
S. Marx,¹ C. Adam,² S. Leyking,² U. Sester,² M. Sester.
¹Saarland University, Homburg/Saar, Germany; ²Saarland University, Homburg/Saar, Germany.
Background: Dosage of immunosuppressive drugs in transplant patients must be balanced to prevent graft rejection and infectious complications. Knowledge on general immune function may therefore…
2018 American Transplant Congress
Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens
Q. Gao, R. Davis, M. Mulvihill, M. Song, F. Leopardi, M. Ribeiro, T. How, G. Devi, B. Collins, A. Kirk.
Department of Surgery, Duke University Medical Center, Durham, NC.
IntroductionThe field of porcine islet xenotransplantation has made significant progress in non-human primate studies in recent years. However, one major barrier preventing clinical translation of…
2018 American Transplant Congress
Experience with Immunosuppressive Strategies in Vascularized Composite Allotransplantation of Face
R. Klasek,¹ B. Kollar,² S. Tasigiorgos,² B. Pomahac.²
¹Department of Pharmacy, Brigham and Women's Hospital, Boston, MA; ²Department of Surgery, Brigham and Women's Hospital, Boston, MA.
This retrospective review of the largest face transplant cohort aims to describe the evolution of immunosuppressive (IS) regimens used in face transplant recipients.All face transplants…
2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
P. Malvezzi,¹ S. Bunnapradist,² D. Stevens,³ M. Moten,³ A. Loh,³ S. Patel,³ L. Rostaing.¹
¹Service De Néphrologie, Hémodialyse, Aphérèses Et Transplantation Rénale, Chu Grenoble Alpes, La Tronche, France; ²Nephrology, University of California, Los Angeles, Los Angeles, CA; ³Veloxis, Cary, NC.
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…
2018 American Transplant Congress
Do We Need to Worry about EBV DNAemia in the Late Post-Transplant Period?
M. Morton,¹ K. Daga,² P. Klapper,² M. Picton,¹ P. Vallely.²
¹Department of Renal Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; ²University of Manchester, Manchester, United Kingdom.
Background: Despite detectable Epstein-Barr virus (EBV) in blood, kidney transplant patients (KTR) may have no apparent clinical consequence. This study aims to explore the clinical…
2018 American Transplant Congress
BK Viremia in Simultaneous Kidney Pancreas Recipients: Single Center Experience
M. Alebrahim,¹ R. Pelletier,¹ A. Rajab,¹ G. Bumgardner,¹ R. Daloul,² C. Akateh,³ K. Washburn,¹ A. El-Hinnawi.¹
¹Transplant Surgery, The Ohio State University Wexner Medical Center, Columbus, OH; ²Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH; ³Surgery, The Ohio State University Wexner Medical Center, Columbus, OH.
Introduction: The impact of BK viremia in recipients of simultaneous pancreas and kidney transplantation (SPK) is not well known. We therefore studied the incidence and…